Johns Hopkins Vaccine mKRAS-VAX Demonstrates Durable Immune Response in Pancreatic Cancer Trial

The mKRAS-VAX vaccine, developed by researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, has shown promising results in a phase 1 trial targeting mutant KRAS, a common mutation in pancreatic cancer. This off-the-shelf synthetic peptide vaccine demonstrated durable tumor-specific T-cell responses in 90% of the 20 high-risk participants. Notably, after a median follow-up of 16.5 months, none of the participants developed pancreatic cancer. These findings suggest potential for the vaccine in cancer interception, aiming to prevent the disease before it manifests clinically.

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at advanced stages, resulting in low survival rates. Most cases are linked to KRAS mutations, which are prevalent in pancreatic cancer. The mKRAS-VAX vaccine targets the six most common KRAS mutations, focusing on individuals at high risk due to hereditary factors or concerning pancreatic lesions. The trial's results indicate that the vaccine can stimulate both effector and memory T-cell responses, which are essential for long-lasting immunity against cancer.

The trial was conducted with careful oversight, engaging high-risk individuals who were monitored for their response to vaccination. Participants exhibited mutant-KRAS-specific T-cell responses that remained detectable in their blood for up to two years. Additionally, researchers observed a higher rate of cyst reduction or resolution among vaccinated individuals compared to an unvaccinated cohort, suggesting a potential preventive effect of the vaccine against the progression of pancreatic lesions.

The broader implications of the mKRAS-VAX vaccine extend beyond individual patient outcomes. By focusing on cancer interception rather than treatment, the vaccine could shift the paradigm in addressing pancreatic cancer. Early intervention may lead to better overall survival rates and reduced morbidity associated with advanced cancer. This approach is particularly critical given the increasing frequency of early-onset pancreatic cancer and the limitations of current early detection methods.

Future studies are planned to further assess the efficacy of the mKRAS-VAX vaccine, including a follow-up trial aimed at determining whether the vaccine-induced T cells can infiltrate precancerous pancreatic tissue. As research progresses, the potential of mKRAS-VAX could contribute significantly to the field of cancer prevention and interception, offering hope for individuals at high risk of developing pancreatic cancer.